Johnson & Johnson (JNJ-N) Stock Predictions - Stockchase
WATCH LIST
410
Johnson & Johnson (JNJ-N)

ON STOCKCHASE SINCE Oct 2000

biotechnology/pharmaceutical

Johnson & Johnson

JNJ-N

159 watching          
Join the Discussion

Johnson & Johnson (JNJ-N) SAVE Mar, 18, 2019, 3:34 pm

136.93 0.67 (0.49%)

About Johnson & Johnson (JNJ-N)

Johnson & Johnson is an American multinational medical devices, pharmaceutical and consumer packaged goods manufacturing company founded in 1886. More at Wikipedia

What the experts are saying about JNJ-N



  • All
  • Filtered
Signal Opinion Expert
TOP PICK
Johnson & Johnson(JNJ-N) 

April 20, 2017

Recently missed on revenues and the stock sold off a bit. They actually beat on the earnings per share. This company has 3 solid lines of business, pharmaceuticals, consumer products and medical devices. There should be significant earnings growth this year. They did a significant acquisition last year which should be coming into earnings this year. Trading at about 20X earnings. Dividend yield of 2.6%. (Analysts’ price target is $130.)

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

Recently missed on revenues and the stock sold off a bit. They actually beat on the earnings per share. This company has 3 solid lines of business, pharmaceuticals, consumer products and medical devices. There should be significant earnings growth this year. They did a significant acquisition last year which should be coming into earnings this year. Trading at about 20X earnings. Dividend yield of 2.6%. (Analysts’ price target is $130.)

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Lorne Zeiler

Portfolio , TriDelta Financial...

Price Price
$121.870
Owned Owned
Yes

COMMENT
Johnson & Johnson(JNJ-N) 

April 19, 2017

One of these great franchise stocks. It is so big, that it is dominant in quite a number of categories. You are going to make 5%-6% per annum over the long term. It is a bond substitute. A fine stock to just Buy and hold forever. You are probably not going to make substantial returns, but you can sleep at night.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

One of these great franchise stocks. It is so big, that it is dominant in quite a number of categories. You are going to make 5%-6% per annum over the long term. It is a bond substitute. A fine stock to just Buy and hold forever. You are probably not going to make substantial returns, but you can sleep at night.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Bruce Murray

CEO & Chie, The Murray Wealth Gr...

Price Price
$121.370
Owned Owned
Unknown

BUY
Johnson & Johnson(JNJ-N) 

March 21, 2017

The pharmaceutical group rolled over in the midwinter of 2015, as Hillary was making her comments about drug companies, so the group was under pressure significantly right through until the end of 2016. What is interesting is that there are new sectors that are starting to kick in gear, and one of them has been healthcare, pharmaceuticals, biotech and healthcare devices. This one looks great. It just made a new high and pulled back a couple of dollars. It is one of the leading stocks in the group. It gives you a nice yield. Expects there are a lot of refugees from the bond market that will be pulling money out as interest rates go higher, and will be looking for companies that can generate a steady stream of growing dividends. This company fits that bill.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

The pharmaceutical group rolled over in the midwinter of 2015, as Hillary was making her comments about drug companies, so the group was under pressure significantly right through until the end of 2016. What is interesting is that there are new sectors that are starting to kick in gear, and one of them has been healthcare, pharmaceuticals, biotech and healthcare devices. This one looks great. It just made a new high and pulled back a couple of dollars. It is one of the leading stocks in the group. It gives you a nice yield. Expects there are a lot of refugees from the bond market that will be pulling money out as interest rates go higher, and will be looking for companies that can generate a steady stream of growing dividends. This company fits that bill.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
David Burrows

President , Barometer Capital Ma...

Price Price
$127.250
Owned Owned
Unknown

HOLD
Johnson & Johnson(JNJ-N) 

March 16, 2017

Hold or sell? With the sectors it is in, consumers, pharmaceuticals and products, it is a bit of a healthcare conglomerate. Given that the demographics are trending in the right direction and drug prices being a little less political than it was, he is constructive on healthcare. If you had to pick one stock as a barometer to all various sectors in healthcare, this would be a good one.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

Hold or sell? With the sectors it is in, consumers, pharmaceuticals and products, it is a bit of a healthcare conglomerate. Given that the demographics are trending in the right direction and drug prices being a little less political than it was, he is constructive on healthcare. If you had to pick one stock as a barometer to all various sectors in healthcare, this would be a good one.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Zachary Curry

Chief Oper, Davis-Rea Ltd....

Price Price
$128.460
Owned Owned
No

COMMENT
Johnson & Johnson(JNJ-N) 

February 22, 2017

Their consumer line is very small on a relative basis, sub 10%. The company is fully diversified. A $325 billion market cap. You are paying a little bit lower than a broader market multiple. They have the ability to really commercialize a drug. Their recent acquisition of Actelion sounds like it is earnings accretive slightly this year and above market growth next year, with greater exposure into the lung market.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

Their consumer line is very small on a relative basis, sub 10%. The company is fully diversified. A $325 billion market cap. You are paying a little bit lower than a broader market multiple. They have the ability to really commercialize a drug. Their recent acquisition of Actelion sounds like it is earnings accretive slightly this year and above market growth next year, with greater exposure into the lung market.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Paul Macdonald

Chief Inve, Harvest Portfolios G...

Price Price
$119.520
Owned Owned
Yes

TOP PICK
Johnson & Johnson(JNJ-N) 

February 17, 2017

They have done well in the pharma side.  They just announced the acquisition of a Swiss based pharma company.  They grow organically also.  They have identified about 10 products they are going to launch in the next three years that have about $1 Billion each.  They trade at 16 times earnings and have increased their dividend for 54 consecutive years.  (Analysts’ target: $126.32).

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

They have done well in the pharma side.  They just announced the acquisition of a Swiss based pharma company.  They grow organically also.  They have identified about 10 products they are going to launch in the next three years that have about $1 Billion each.  They trade at 16 times earnings and have increased their dividend for 54 consecutive years.  (Analysts’ target: $126.32).

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Christine Poole

CEO & Mana, GlobeInvest Capital ...

Price Price
$118.860
Owned Owned
Yes

COMMENT
Johnson & Johnson(JNJ-N) 

January 27, 2017

Merck (MRK-N) or Johnson & Johnson (JNJ-N) for safety? For safety, he would attribute that more to this company. They have a great yield of about 2.8%, but keep in mind that as a Canadian investor, you do not get the dividend tax credit. This company has the pharma, medical devices and consumer products. The bet you are making is that they are going to be able to turn around the recent acquisition of the devices business, and that is a big bet, because they spent a lot of money. Expects some share price volatility over the next 6-18 months.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

Merck (MRK-N) or Johnson & Johnson (JNJ-N) for safety? For safety, he would attribute that more to this company. They have a great yield of about 2.8%, but keep in mind that as a Canadian investor, you do not get the dividend tax credit. This company has the pharma, medical devices and consumer products. The bet you are making is that they are going to be able to turn around the recent acquisition of the devices business, and that is a big bet, because they spent a lot of money. Expects some share price volatility over the next 6-18 months.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Kash Pashootan

CEO & Chie, First Avenue Investm...

Price Price
$113.380
Owned Owned
No

DON'T BUY
Johnson & Johnson(JNJ-N) 

January 26, 2017

They made a major acquisition today.  The largest pharma in Europe, trying to pick up the drug.  JNJ is a well run company.  They were split evenly in the past between their businesses, but now the pharma is starting to dominate.  They are no longer to be compared with the consumer space.  But it is not a compelling opportunity to him based on fundamentals.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

They made a major acquisition today.  The largest pharma in Europe, trying to pick up the drug.  JNJ is a well run company.  They were split evenly in the past between their businesses, but now the pharma is starting to dominate.  They are no longer to be compared with the consumer space.  But it is not a compelling opportunity to him based on fundamentals.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Gordon Reid

President, GoodReid Investment ...

Price Price
$111.840
Owned Owned
Unknown

BUY
Johnson & Johnson(JNJ-N) 

January 25, 2017

A very well-managed company with a very solid footing. Valuation is reasonable and certainly belongs in a portfolio. It is more of a stabilizer rather than a driver of volatility. In the last couple of days, there has been some concern when guidance came in the little bit lower. He wouldn’t be surprised to see them make some acquisitions in 2017. 2.9% dividend yield.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

A very well-managed company with a very solid footing. Valuation is reasonable and certainly belongs in a portfolio. It is more of a stabilizer rather than a driver of volatility. In the last couple of days, there has been some concern when guidance came in the little bit lower. He wouldn’t be surprised to see them make some acquisitions in 2017. 2.9% dividend yield.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Dr. Richard Eva

Head of He, SSR...

Price Price
$112.800
Owned Owned
Unknown

HOLD
Johnson & Johnson(JNJ-N) 

January 24, 2017

The kind of stock you can put in the “buy, hold and forget about it” category. They have some well recognized brands. He doesn’t know what the Trump effect would be on this type of company. The company has a tremendous history of increasing shareholder wealth through increasing earnings per share, and increasing shareholder equity through their very attractive ROE.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

The kind of stock you can put in the “buy, hold and forget about it” category. They have some well recognized brands. He doesn’t know what the Trump effect would be on this type of company. The company has a tremendous history of increasing shareholder wealth through increasing earnings per share, and increasing shareholder equity through their very attractive ROE.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Jason Del Vicar

Portfolio , HollisWealth...

Price Price
$111.760
Owned Owned
Unknown

COMMENT
Johnson & Johnson(JNJ-N) 

January 19, 2017

A very well-run company. It has a huge number of products. It has a decent dividend and a good quality balance sheet. It has really been a growth by acquisition. Regarding the consumer products part of it, as Amazon (AMZN-Q) increasingly attracts shoppers, does this company capture part of that margin that is being taken away from retail and grocery stores? Can they allocate their advertising budget more efficiently and effectively? If these companies do start capturing part of that margin, ensuring that part of their profit with Amazon, then he thinks they are interesting. In the interim, he doesn’t think these are all that interesting.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

A very well-run company. It has a huge number of products. It has a decent dividend and a good quality balance sheet. It has really been a growth by acquisition. Regarding the consumer products part of it, as Amazon (AMZN-Q) increasingly attracts shoppers, does this company capture part of that margin that is being taken away from retail and grocery stores? Can they allocate their advertising budget more efficiently and effectively? If these companies do start capturing part of that margin, ensuring that part of their profit with Amazon, then he thinks they are interesting. In the interim, he doesn’t think these are all that interesting.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
John O'Connell,

Chairman a, Davis Rea...

Price Price
$114.200
Owned Owned
No

COMMENT
Johnson & Johnson(JNJ-N) 

January 17, 2017

A wonderful company. His only reservation is, if looking for healthcare, this company has a lot of over-the-counter of hairsprays, Band-Aids, etc. They have a wonderful dividend.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

A wonderful company. His only reservation is, if looking for healthcare, this company has a lot of over-the-counter of hairsprays, Band-Aids, etc. They have a wonderful dividend.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
David Dietze

Founder, P, Point View Wealth Ma...

Price Price
$114.870
Owned Owned
Unknown

BUY on WEAKNESS
Johnson & Johnson(JNJ-N) 

January 12, 2017

A great unique company and business model.  Pharma and personal care consumer businesses.  If you built a position at these levels you probably won’t regret it.  It will be akin to US GDP growth.  It will not be in the cross hairs of any pharma policy changes.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

A great unique company and business model.  Pharma and personal care consumer businesses.  If you built a position at these levels you probably won’t regret it.  It will be akin to US GDP growth.  It will not be in the cross hairs of any pharma policy changes.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Mohsin Bashir

VP Investm, Stone Asset Manageme...

Price Price
$114.620
Owned Owned
Unknown

PAST TOP PICK
Johnson & Johnson(JNJ-N) 

December 30, 2016

(A Top Pick Dec 31/15. Up 15.82%.) Sold his holdings as he felt it had run up a lot, and he had found other opportunities. You can’t go wrong owning this, but he just wanted to put money someplace else.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

(A Top Pick Dec 31/15. Up 15.82%.) Sold his holdings as he felt it had run up a lot, and he had found other opportunities. You can’t go wrong owning this, but he just wanted to put money someplace else.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Paul Harris, CF

Portfolio , Avenue Investment Ma...

Price Price
$115.210
Owned Owned
No

COMMENT
Johnson & Johnson(JNJ-N) 

December 23, 2016

One of the names you want to hold in the pharmaceutical healthcare area for the long term. The pharmaceutical healthcare field has had good earnings growth, and are expecting significant earnings growth next year, especially on the pharmacy side. These kinds of names were really hurt in 2016, because there was fear that if Clinton came in, they are going to start regulating prices along with additional regulations on the pharmaceutical industry. This trades at a premium to the group at about 20-21 times earnings. They have a great platform with a pipeline of about 10 medications that should be coming on market in the next 5 years. They are great at cost cutting. Also there is a potential acquisition they are looking at.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

One of the names you want to hold in the pharmaceutical healthcare area for the long term. The pharmaceutical healthcare field has had good earnings growth, and are expecting significant earnings growth next year, especially on the pharmacy side. These kinds of names were really hurt in 2016, because there was fear that if Clinton came in, they are going to start regulating prices along with additional regulations on the pharmaceutical industry. This trades at a premium to the group at about 20-21 times earnings. They have a great platform with a pipeline of about 10 medications that should be coming on market in the next 5 years. They are great at cost cutting. Also there is a potential acquisition they are looking at.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Lorne Zeiler

Portfolio , TriDelta Financial...

Price Price
$115.960
Owned Owned
Unknown

Showing 46 to 60 of 410 entries
Successfully Saved Company
Successfully Saved Company
8+
JOIN THE DISCUSSION
8 comments in the last 7 days